Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid

Phunchai Charatcharoenwitthaya, Jayant A. Talwalkar, Paul Angulo, Andrea A. Gossard, Jill C. Keach, Janice L. Petz, Roberta A. Jorgensen, Keith Lindor

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We evaluated the safety and efficacy of moexipril, an angiotensin-converting enzyme inhibitor, in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA). Twenty PBC patients on UDCA (13-15 mg/kg/day) therapy with an elevation of serum alkaline phosphatase at least twice the upper limit of normal were treated with oral moexipril 15 mg/day for one year. No significant changes in serum alkaline phosphatase (379 ± 32 vs. 379 ± 51), bilirubin (0.8 ± 0.1 vs. 0.9 ± 0.1), aspartate aminotransferase (60 ± 8 vs. 63 ± 9), and Mayo risk score (3.55 ± 0.2 vs. 3.62 ± 0.2) was associated with the treatment. Fatigue and health-related quality of life scores during treatment demonstrated a trend toward improvement. Moexipril was not clinically beneficial to PBC patients responding suboptimally to UDCA.

Original languageEnglish (US)
Pages (from-to)476-483
Number of pages8
JournalDigestive Diseases and Sciences
Volume55
Issue number2
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Alkaline Phosphatase
Liver
Aspartate Aminotransferases
Serum
Bilirubin
Angiotensin-Converting Enzyme Inhibitors
Angiotensin II
Fatigue
Fibrosis
Theoretical Models
Therapeutics
Quality of Life
Safety
Wounds and Injuries
moexipril

Keywords

  • Angiotensin-converting enzyme inhibitor
  • Primary biliary cirrhosis
  • Treatment
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. / Charatcharoenwitthaya, Phunchai; Talwalkar, Jayant A.; Angulo, Paul; Gossard, Andrea A.; Keach, Jill C.; Petz, Janice L.; Jorgensen, Roberta A.; Lindor, Keith.

In: Digestive Diseases and Sciences, Vol. 55, No. 2, 02.2010, p. 476-483.

Research output: Contribution to journalArticle

Charatcharoenwitthaya, P, Talwalkar, JA, Angulo, P, Gossard, AA, Keach, JC, Petz, JL, Jorgensen, RA & Lindor, K 2010, 'Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid', Digestive Diseases and Sciences, vol. 55, no. 2, pp. 476-483. https://doi.org/10.1007/s10620-009-0744-1
Charatcharoenwitthaya, Phunchai ; Talwalkar, Jayant A. ; Angulo, Paul ; Gossard, Andrea A. ; Keach, Jill C. ; Petz, Janice L. ; Jorgensen, Roberta A. ; Lindor, Keith. / Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. In: Digestive Diseases and Sciences. 2010 ; Vol. 55, No. 2. pp. 476-483.
@article{a9f5c6fb4644421c8a409a0420902f9f,
title = "Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid",
abstract = "Blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We evaluated the safety and efficacy of moexipril, an angiotensin-converting enzyme inhibitor, in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA). Twenty PBC patients on UDCA (13-15 mg/kg/day) therapy with an elevation of serum alkaline phosphatase at least twice the upper limit of normal were treated with oral moexipril 15 mg/day for one year. No significant changes in serum alkaline phosphatase (379 ± 32 vs. 379 ± 51), bilirubin (0.8 ± 0.1 vs. 0.9 ± 0.1), aspartate aminotransferase (60 ± 8 vs. 63 ± 9), and Mayo risk score (3.55 ± 0.2 vs. 3.62 ± 0.2) was associated with the treatment. Fatigue and health-related quality of life scores during treatment demonstrated a trend toward improvement. Moexipril was not clinically beneficial to PBC patients responding suboptimally to UDCA.",
keywords = "Angiotensin-converting enzyme inhibitor, Primary biliary cirrhosis, Treatment, Ursodeoxycholic acid",
author = "Phunchai Charatcharoenwitthaya and Talwalkar, {Jayant A.} and Paul Angulo and Gossard, {Andrea A.} and Keach, {Jill C.} and Petz, {Janice L.} and Jorgensen, {Roberta A.} and Keith Lindor",
year = "2010",
month = "2",
doi = "10.1007/s10620-009-0744-1",
language = "English (US)",
volume = "55",
pages = "476--483",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid

AU - Charatcharoenwitthaya, Phunchai

AU - Talwalkar, Jayant A.

AU - Angulo, Paul

AU - Gossard, Andrea A.

AU - Keach, Jill C.

AU - Petz, Janice L.

AU - Jorgensen, Roberta A.

AU - Lindor, Keith

PY - 2010/2

Y1 - 2010/2

N2 - Blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We evaluated the safety and efficacy of moexipril, an angiotensin-converting enzyme inhibitor, in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA). Twenty PBC patients on UDCA (13-15 mg/kg/day) therapy with an elevation of serum alkaline phosphatase at least twice the upper limit of normal were treated with oral moexipril 15 mg/day for one year. No significant changes in serum alkaline phosphatase (379 ± 32 vs. 379 ± 51), bilirubin (0.8 ± 0.1 vs. 0.9 ± 0.1), aspartate aminotransferase (60 ± 8 vs. 63 ± 9), and Mayo risk score (3.55 ± 0.2 vs. 3.62 ± 0.2) was associated with the treatment. Fatigue and health-related quality of life scores during treatment demonstrated a trend toward improvement. Moexipril was not clinically beneficial to PBC patients responding suboptimally to UDCA.

AB - Blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We evaluated the safety and efficacy of moexipril, an angiotensin-converting enzyme inhibitor, in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA). Twenty PBC patients on UDCA (13-15 mg/kg/day) therapy with an elevation of serum alkaline phosphatase at least twice the upper limit of normal were treated with oral moexipril 15 mg/day for one year. No significant changes in serum alkaline phosphatase (379 ± 32 vs. 379 ± 51), bilirubin (0.8 ± 0.1 vs. 0.9 ± 0.1), aspartate aminotransferase (60 ± 8 vs. 63 ± 9), and Mayo risk score (3.55 ± 0.2 vs. 3.62 ± 0.2) was associated with the treatment. Fatigue and health-related quality of life scores during treatment demonstrated a trend toward improvement. Moexipril was not clinically beneficial to PBC patients responding suboptimally to UDCA.

KW - Angiotensin-converting enzyme inhibitor

KW - Primary biliary cirrhosis

KW - Treatment

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=76849086042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76849086042&partnerID=8YFLogxK

U2 - 10.1007/s10620-009-0744-1

DO - 10.1007/s10620-009-0744-1

M3 - Article

C2 - 19255851

AN - SCOPUS:76849086042

VL - 55

SP - 476

EP - 483

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 2

ER -